Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

Powles, Thomas; Choueiri, Toni K; Motzer, Robert J; Jonasch, Eric; Pal, Sumanta; Tannir, Nizar M; Signoretti, Sabina; Kaldate, Rajesh; Scheffold, Christian; Wang, Evelyn; Aftab, Dana T; Escudier, Bernard; George, Daniel J

Powles, Thomas; Choueiri, Toni K; Motzer, Robert J; Jonasch, Eric; Pal, Sumanta; Tannir, Nizar M; Signoretti, Sabina; Kaldate, Rajesh; Scheffold, Christian; Wang, Evelyn; Aftab, Dana T; Escudier, Bernard; George, Daniel J.

Afiliação

Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK. thomas.powles1@nhs.net.
Choueiri TK; Dana-Farber Cancer Center, Boston, MA, USA.
Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonasch E; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pal S; City of Hope National Medical Center, Duarte, CA, USA.
Tannir NM; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Signoretti S; Brigham and Women's Hospital, Boston, MA, USA.
Kaldate R; Exelixis, Inc, Alameda, CA, USA.
Scheffold C; Exelixis, Inc, Alameda, CA, USA.
Wang E; Exelixis, Inc, Alameda, CA, USA.
Aftab DT; Exelixis, Inc, Alameda, CA, USA.
Escudier B; Gustave-Roussy, Villejuif, France.
George DJ; Duke Cancer Institute, Durham, NC, USA.

BMC Cancer ; 21(1): 1023, 2021 Sep 15.

Article em En | MEDLINE | ID: mdl-34525968

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: BMC Cancer Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google